U-CyTech Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 2

U-CyTech General Information

Description

Developer of biomedical products designed to offer immunoassays for human, monkey, and rodent use. The company's products include cytokine enzyme-linked immunosorbent assays, T and B cell assays, and enzyme-linked Immuno spot systems which are designed for the ex vivo detection of individual protein-secreting cells, enabling clients to prepare efficient medicines for their biological research.

Contact Information

Website
www.ucytech.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Yalelaan 48
  • 3584 CM Utrecht
  • Netherlands
+31 085
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • Yalelaan 48
  • 3584 CM Utrecht
  • Netherlands
+31 085

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

U-CyTech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 01-Jan-1999 Completed Generating Revenue
1. University Spin-Out 01-Jan-1999 Completed Generating Revenue
To view U-CyTech’s complete valuation and funding history, request access »

U-CyTech Patents

  • 6

    Total Documents Applications and Grants

  • Total Patents Families

  • 1

    Granted

  • Pending

  • Expiring in next 12 mo

U-CyTech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20040136957-A1 Administering a therapeutically relevant dose of ifn (interferon) type-i or a functional part, derivative and/or analogue thereof Inactive 03-Apr-2001
EP-1377303-A2 Method for reducing cellular damage resulting from hypoxia/ischaemia-related inflammation Inactive 03-Apr-2001
EP-1372702-A1 Method of treatment of hypoxia/ischaemia related blood flow resistance Active 03-Apr-2001
US-20040105843-A1 Prevention of cellular damage in disease resulting from h/i-related blood flow resistance due to occlusion of blood vessels Inactive 03-Apr-2001
EP-1372702-B1 Treatment of hypoxia/ischaemia related blood flow resistance using beta-interferon Inactive 03-Apr-2001 A61K38/212
To view U-CyTech’s complete patent history, request access »

U-CyTech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

U-CyTech Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Utrecht Holdings Not-For-Profit Venture Capital Minority
Utrecht University University
To view U-CyTech’s complete investors history, request access »

Ready to get started?

Request a free trial

U-CyTech FAQs

  • When was U-CyTech founded?

    U-CyTech was founded in 1999.

  • Where is U-CyTech headquartered?

    U-CyTech is headquartered in Utrecht, Netherlands.

  • What is the size of U-CyTech?

    U-CyTech has 8 total employees.

  • What industry is U-CyTech in?

    U-CyTech’s primary industry is Biotechnology.

  • Is U-CyTech a private or public company?

    U-CyTech is a Private company.

  • What is U-CyTech’s current revenue?

    The current revenue for U-CyTech is .

  • Who are U-CyTech’s investors?

    Utrecht Holdings and Utrecht University have invested in U-CyTech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »